Dataset Information

Mesenchymal stem cell-derived exosomal miR-146a reverses diabetic β-cell dedifferentiation.

ABSTRACT:

Background

Mesenchymal stem cells (MSCs) show promising therapeutic potential in treating type 2 diabetes mellitus (T2DM) in clinical studies. Accumulating evidence has suggested that the therapeutic effects of MSCs are not due to their direct differentiation into functional β-cells but are instead mediated by their paracrine functions. Among them, exosomes, nano-sized extracellular vesicles, are important substances that exert paracrine functions. However, the underlying mechanisms of exosomes in ameliorating T2DM remain largely unknown.

Methods

Bone marrow mesenchymal stem cell (bmMSC)-derived exosomes (bmMDEs) were administrated to T2DM rats and high-glucose-treated primary islets in order to detect their effects on β-cell dedifferentiation. Differential miRNAs were then screened via miRNA sequencing, and miR-146a was isolated after functional verification. TargetScan, reporter gene detection, insulin secretion assays, and qPCR validation were used to predict downstream target genes and involved signaling pathways of miR-146a.

Results

Our results showed that bmMDEs reversed diabetic β-cell dedifferentiation and improved β-cell insulin secretion both in vitro and in vivo. Results of miRNA sequencing in bmMDEs and subsequent functional screening demonstrated that miR-146a, a highly conserved miRNA, improved β-cell function. We further found that miR-146a directly targeted Numb, a membrane-bound protein involved in cell fate determination, leading to activation of β-catenin signaling in β-cells. Exosomes derived from miR-146a-knockdown bmMSCs lost the ability to improve β-cell function.

Conclusions

These findings demonstrate that bmMSC-derived exosomal miR-146a protects against diabetic β-cell dysfunction by acting on the NUMB/β-catenin signaling pathway, which may represent a novel therapeutic strategy for T2DM.

SUBMITTER: He Q

PROVIDER: S-EPMC8356465 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Mesenchymal stem cell-derived exosomal miR-146a reverses diabetic β-cell dedifferentiation.

He Qin Q Song Jia J Cui Chen C Wang Jinbang J Hu Huiqing H Guo Xinghong X Yang Mengmeng M Wang Lingshu L Yan Fei F Liang Kai K Liu Zhaojian Z Liu Fuqiang F Sun Zheng Z Dong Ming M Hou Xinguo X Chen Li L

Stem cell research & therapy 20210811 1

<h4>Background</h4>Mesenchymal stem cells (MSCs) show promising therapeutic potential in treating type 2 diabetes mellitus (T2DM) in clinical studies. Accumulating evidence has suggested that the therapeutic effects of MSCs are not due to their direct differentiation into functional β-cells but are instead mediated by their paracrine functions. Among them, exosomes, nano-sized extracellular vesicles, are important substances that exert paracrine functions. However, the underlying mechanisms of e ...[more]

PMID: 34380570

Similar Datasets

Project description:Introduction Ischemic diseases caused by diabetes continue to pose a major health challenge and effective treatments are in high demand. Mesenchymal stem cells (MSCs) derived exosomes have aroused broad attention as a cell-free treatment for ischemic diseases. However, the efficacy of exosomes from adipose-derived mesenchymal stem cells (ADSC-Exos) in treating diabetic lower limb ischemic injury remains unclear. Methods Exosomes were isolated from ADSCs culture supernatants by differential ultracentrifugation and their effect on C2C12 cells and HUVECs was assessed by EdU, Transwell, and in vitro tube formation assays separately. The recovery of limb function after ADSC-Exos treatment was evaluated by Laser-Doppler perfusion imaging, limb function score, and histological analysis. Subsequently, miRNA sequencing and rescue experiments were performed to figure out the responsible miRNA for the protective role of ADSC-Exos on diabetic hindlimb ischemic injury. Finally, the direct target of miRNA in C2C12 cells was confirmed by bioinformatic analysis and dual-luciferase report gene assay. Results ADSC-Exos have the potential to promote proliferation and migration of C2C12 cells and to promote HUVECs angiogenesis. In vivo experiments have shown that ADSC-Exos can protect ischemic skeletal muscle, promote the repair of muscle injury, and accelerate vascular regeneration. Combined with bioinformatics analysis, miR-125b-5p may be a key molecule in this process. Transfer of miR-125b-5p into C2C12 cells was able to promote cell proliferation and migration by suppressing ACER2 overexpression. Conclusion The findings revealed that miR-125b-5p derived from ADSC-Exos may play a critical role in ischemic muscle reparation by targeting ACER2. In conclusion, our study may provide new insights into the potential of ADSC-Exos as a treatment option for diabetic lower limb ischemia. Supplementary Information The online version contains supplementary material available at 10.1186/s12951-023-01954-8. Highlights ADSC-Exos have the potential to facilitate muscle repair in the context of diabetes. miR-125b-5p derived from ADSC-Exos played a crucial role in muscle injury. The primary biological function of miR-125b-5p is achieved by targeting ACER2. The AMPK signaling pathway may play a significant role in diabetic hindlimb ischemia. Supplementary Information The online version contains supplementary material available at 10.1186/s12951-023-01954-8.

Dataset Information

Mesenchymal stem cell-derived exosomal miR-146a reverses diabetic β-cell dedifferentiation.

Background

Methods

Results

Conclusions

Publications

Mesenchymal stem cell-derived exosomal miR-146a reverses diabetic β-cell dedifferentiation.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets